Abstract
Infections by Cunninghamella bertholletiae have been on the increase in recent years. However, little is known about this fungus and its infection. To clarify the pathogenicity of C. bertholletiae, we made a murine model, and to our knowledge, the first infectious model of this fungus. ICR mice pretreated with cortisone acetate and cyclophosphamide were inoculated intratracheally with 5 × 105 spores of C. bertholletiae. About half of the mice died by day 4 and 90% died by day 9. C. bertholletiae was cultured from the lungs, and the pathological analysis disclosed diffuse hyphal growth in the lungs, resulting in necrosis in the later stage. Angioinvasion with alveolar hemorrhage was extremely pronounced from the early stage, and this was the most characteristic feature of this infection. Treatment with amphotericin B showed only minimal improvement of survival, comparable to the poor result of this treatment in actual human cases. In fact, our model has many similarities to the actual human infection by C. bertholletiae, and will be useful for further investigations of this infection.
Similar content being viewed by others
References
Walsh TJ, Karp J, Pizzo PA. Fungal infections of the respiratory tract. In: Kibbler CC, Mackenzie DWR, Odds FC, eds. Principles and practice of medical mycology. Chichester: John Wiley and Sons 1996: 235‐268.
Cohen-Abbo A, Bozeman PM, Patrick CC. Cunninghamella infections: Review and report of two cases of Cunninghamella pneumonia in immunocompromised children. Clin Infect Dis 1993; 17: 173‐177.
Weitzman I, Crist MY. Studies with clinical isolates of Cunninghamella. II. Physiological and morphological studies. Mycologia 1980; 72: 661‐669.
Kwong-Chung KJ, Bennett JE. Mucormycosis. In: Medical mycology. Philadelphia: Lea & Febiger 1992: 524‐559.
Kontoyianis DP, Vartivarian S, Anaissie EJ, Samonis G, Bodey GP, Rinaldi M. Infections due to Cunninghamella bertholletiae in patients with cancer: Report of three cases and review. Clin Infect Dis 1994; 18: 925‐928.
Shishihara T, Kamei K, Edo H, Kuriyama T, Nishimura K, Miyaji M. A case of lung mucormycosis with erythroderma caused by Cunninghamella bertholletiae. Resp Res 1997; 16: 967‐971.
Maloisel F, Dufour P, WaIler J, Herbrecht R, Marcellin L, Koenig H, Liu KL, Weber J-C, Bergerat J-P, Oberling F. Cunninghamella bertholletiae: An uncommon agent of opportunistic fungal infection. Nouv Rev Fr Hematol 1991; 33: 311‐315.
Hutter RVP. Phycomycetous infection (mucormycosis) in cancer patients: A complication of therapy. Cancer 1959; 12: 330‐350.
Ng TTC, Campbell CK, Rothera M, Houghton JB, Hughes D, Denning DW. Successful treatment of sinusitis caused by Cunninghamella bertholletiae. Clin Infect Dis 1994; 19: 313‐316.
Goldani L, Sugar AM. Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug. J Antimicrob Chemother 1994; 33: 369‐372.
Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 1984; 150: 752‐760.
Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984; 74: 150‐160.
Anand VK, Alemar G, Griswold Jr JA. Intracranial complications of mucormycosis: An experimental model and clinical review. Laryngoscope 1992; 102: 656‐662.
Abe F, Inaba H, Katoh T, Hotchi M. Effects of iron and desferrioxamine on Rhizopus infection. Mycopathol 1990; 110: 87‐91.
Boelaert JR, van Cutsem J, de Locht M, Schneider Y, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney International 1994; 45: 667‐671.
Jensen HE, Aalbæk B, Hau J. Induction of systemic zygomycosis in pregnant mice by Absidia corymbifera. Laboratory Animal Science 1995; 45: 254‐257.
Sodhi MPS, Khanna RNS, Chand P. Experimental Absidia corymbifera infection in rabbits: Clinicopathological studies. Mycopathol 1996; 134: 7‐11.
Waldorf AR, Halde C, Vedros NA. Murine model of pulmonary mucormycosis in cortisone-treated mice. Sabouraudia 1982; 20: 217‐224.
Walsh TJ, Rinaldi MR, Pizzo PA. Zygomycosis of the respiratory tract. In: Sarosi GA, Davies SF, eds. Fungal diseases of the lung. 2nd ed. New York: Raven Press 1993: 149‐170.
Diamond RD, Krzesicki R, Epstein B, Jao W. Damage to hyphal forms of fungi by human leukocytes in vitro. A possible host defense mechanism in aspergillosis and mucormycosis. Amer J Pathol 1978; 91: 313‐328.
Schell WA, Johnson MG, McGinnis MR, Weitzman I, Crist MY. Zygomycosis caused by Cunninghamella bertholletiae. Arch Pathol Lab Med 1982; 106: 287‐291.
Sugar AM. Agents of mucormycosis and related species. In: Mandell GL, Douglas Jr RG, Bennett JE, eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone 1990: 1962‐1972.
Rights and permissions
About this article
Cite this article
Honda, A. A murine model of zygomycosis by Cunninghamella bertholletiae. Mycopathologia 144, 141–146 (1998). https://doi.org/10.1023/A:1007095831301
Issue Date:
DOI: https://doi.org/10.1023/A:1007095831301